BioMed Realty Trust VP Unloads $153,370 in Stock (BMR)
BioMed Realty Trust (NYSE:BMR) VP Matthew G. Mcdevitt sold 7,000 shares of BioMed Realty Trust stock on the open market in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $21.91, for a total value of $153,370.00. Following the completion of the sale, the vice president now directly owns 138,328 shares in the company, valued at approximately $3,030,766. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
BMR has been the subject of a number of recent research reports. Analysts at Robert W. Baird raised their price target on shares of BioMed Realty Trust from $22.00 to $23.00 in a research note on Tuesday, May 13th. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of BioMed Realty Trust in a research note on Thursday, April 17th. They now have a $23.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of BioMed Realty Trust from $20.00 to $22.00 in a research note on Tuesday, March 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. BioMed Realty Trust currently has an average rating of “Buy” and a consensus price target of $22.71.
Shares of BioMed Realty Trust (NYSE:BMR) traded up 0.64% during mid-day trading on Tuesday, hitting $22.02. 1,865,712 shares of the company’s stock traded hands. BioMed Realty Trust has a 1-year low of $17.90 and a 1-year high of $21.89. The stock’s 50-day moving average is $21.01 and its 200-day moving average is $19.82. The company has a market cap of $4.204 billion and a P/E ratio of 88.94.
BioMed Realty Trust (NYSE:BMR) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.35 by $0.03. On average, analysts predict that BioMed Realty Trust will post $1.49 earnings per share for the current fiscal year.
BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.